कंपनी का अवलोकन
OneMedNet Corporation operates within the healthcare sector, specifically focusing on the Health Information Services industry by providing digital medical image management, exchange, and sharing solutions across the Americas, Europe, and the Middle East. The company's core product offering includes iRWD, which delivers regulatory-grade imaging and clinical data tailored for the pharmaceutical and device manufacturing sectors. This micro-cap enterprise holds a market capitalization of $45.94M, reflecting its small-scale positioning in the broader healthcare technology landscape. With an annual revenue of $1.36M and an unlisted employee count, the company operates with minimal operational footprint, indicating a niche business model that relies heavily on software licensing rather than extensive physical infrastructure or large workforce deployment.
वित्तीय स्वास्थ्य
The company reported a total revenue of $1.36M for the trailing twelve months, yet it posted a net income of $-2,801,000 and an EBITDA of $-9,602,000, revealing a severe structural cost inefficiency where expenses drastically outpace income generation. The free cash flow stands at $-7,840,750, which signifies a negative financial flexibility where the business is consuming its available liquidity to fund operations or growth initiatives. Analysis of the profit margins shows a gross margin of -37.0%, an operating margin of -345.9%, and a profit margin of -206.1%, all of which indicate that the company is operating at a significant loss across every level of its income statement. Regarding balance sheet leverage, the firm holds $585,000 in cash against $974,000 in debt, resulting in a negative price-to-book ratio of -15.44 and a debt-to-equity ratio that is not disclosed, suggesting a capital structure heavily weighted against equity value. The current ratio is recorded at 0.43, indicating that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity constraints. Furthermore, the Return on Equity is not available due to the negative equity position, while the Return on Assets is -205.6%, which reveals that the management team is generating substantial losses relative to the assets employed in the business.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not available due to the lack of net income, and the forward P/E is also not available, preventing a direct comparison of expected earnings trajectories or growth expectations based on traditional multiples. The price-to-book ratio is listed at -15.44, a metric that typically indicates a distressed asset or a company with negative shareholder equity, rather than a market premium over book value. Alternative valuation metrics such as the price-to-sales ratio of 33.80 and an EV/EBITDA of -4.83 suggest that the market is pricing the company based on revenue potential despite the negative earnings and enterprise value multiples. The stock has traded within a 52-week range with a high of $4.22 and a low of $0.30, placing the current trading price significantly below the recent highs and reflecting the high volatility associated with small-cap healthcare software firms. The beta value is 1.17, which implies that the stock price is more volatile than the broader market and tends to amplify market movements, particularly in the biotech and health information technology sectors.
Growth & Income
The company experienced a revenue growth rate of 3326.9% year-over-year, while the earnings growth rate is not available, implying that the massive top-line expansion has not yet translated into profitability or positive bottom-line results. As a non-dividend payer, OneMedNet Corporation does not distribute a dividend yield or maintain a payout ratio, meaning the company retains all generated funds, or in this case, utilizes reserves to offset operational deficits rather than returning capital to shareholders. This reinvestment strategy is common for early-stage technology firms attempting to achieve operational break-even before establishing a sustainable dividend program. The overall growth and income profile is characterized by explosive top-line expansion coupled with persistent losses and negative cash flow, indicating a high-risk, high-reward trajectory typical of speculative healthcare software ventures.